ClinicalTrials.Veeva

Menu

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

Allergan logo

Allergan

Status and phase

Completed
Phase 4

Conditions

Inflammation

Treatments

Drug: Ketorolac 0.4%
Drug: Lubricating Eye Drop

Study type

Interventional

Funder types

Industry

Identifiers

NCT00791323
MA-ACU-08-001

Details and patient eligibility

About

A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy

Enrollment

9 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients scheduled to undergo phakic IOL implantation

Exclusion criteria

  • History of intraocular surgery in the operative eye

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

9 participants in 2 patient groups

1
Active Comparator group
Description:
Ketorolac 0.4%
Treatment:
Drug: Ketorolac 0.4%
2
Active Comparator group
Description:
Mineral Oil Emollient
Treatment:
Drug: Lubricating Eye Drop

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems